Over the past decade, major changes have taken place in the field of drug targets. Although the traditional target is still the main direction, the R&D trend is gradually shifting from traditionalRead More…
Pros and Cons of PROTAC Technology
Advantages of PROTAC technology Through PROTAC technology, it is possible to develop drugs against undruggable or difficult-to-drug targets of traditional inhibitors. The PROTAC does not rely on the active site ofRead More…
PROTAC, a Frontier Small Molecule Drug
On December 14, 2020, Arvinas, a pioneer of PROTAC, announced the results of phase I clinical trials of new PROTAC drugs ARV-471 and ARV-110, of which ARV-471 showed outstanding efficacy in patientsRead More…
Breaking: Class 1 Innovative Small-molecule BTK-PROTAC Antineoplastic Drugs Approved
On January 26th, the application for the clinical trial of HSK29116 powder declared by Sichuan Haisco Pharmaceutical Co., Ltd. was accepted by the State Food and Drug Administration. HSK29116 is an oralRead More…
PROTAC–Opportunities and Challenges
PROTAC is a novel technique that induces targeted protein degradation by the ubiquitin-proteasome system (UPS). Different from the traditional occupation-driven pharmacological principles, event-driven PROTAC technology has many advantages, such as high activity,Read More…
A Deeper Look into PROTAC Technology
Over the past decade, major changes have taken place in the field of drug targets. Although traditional targets (such as kinases and G-protein-coupled receptors) are still the main stream, the focus isRead More…
New PROTAC Interim Data Released—Potential ARV-471 Won Arvinas Doubled Shares
On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…
Focus on PROTAC—Target Summary from 2001 to 2019
PROTAC, of which the full name is proteolysis-targeting chimera, looks like a dumbbell and mainly consists of a linker, a ligand of interest protein, and a ligand recruiting E3 ubiquitin ligase. InRead More…
Basic Research Progress of PROTAC in Hematological Diseases-Part Two
In addition to the T-cell Lymphoma,T-cell Acute Lymphoblastic Leukaemia mentioned in our previous article, there are also related studies of protac in other blood diseases. Next, let’s analyze the research of protacRead More…
Basic Research Progress of PROTAC in Hematological Diseases-Part one
Proteolysis targeted chimera (PROTAC) is a rapidly developed technology in recent years, which provides the possibility for many undruggable targets, and has become the focus of protein drug researchers. Hematologic malignancies areRead More…